Cost Saving Opportunities in NSCLC Therapy by Optimized Diagnostics

With an incidence of 68 new cases per 100,000 people per year, an estimated total number of up to 350,000 new non-small-cell lung cancer (NSCLC) cases are diagnosed each year in the European Union. Up to 10% of NSCLC patients are eligible for therapy with novel ALK (anaplastic lymphoma kinase) inhib...

Full description

Saved in:
Bibliographic Details
Published in:Cancers (Basel)
Main Authors: Nenadić, Ilija, Staber, Janine, Dreier, Susanne, Simons, Guus, Schildgen, Verena, Brockmann, Michael, Schildgen, Oliver
Format: Artigo
Language:Inglês
Published: MDPI 2017
Subjects:
Opinion
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC5532624/
https://ncbi.nlm.nih.gov/pubmed/28696381
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/cancers9070088
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items